UK review of obesity pill orforglipron stays open after NICE asks Lilly for more information
British coverage of the obesity pill orforglipron is still unresolved after reviewers asked Lilly for more information, a reminder that approval and insurance coverage are separate decisions.
The UK's National Institute for Health and Care Excellence has asked Eli Lilly for more information about orforglipron after its first committee meeting on the weight-loss pill [1]. No date has been set for a second review, and the appraisal remains open [1]. The appraisal listing carries an expected publication date of 18 November 2026 [1].
NICE decides whether medicines are available through the National Health Service. Orforglipron, sold as Foundayo, was authorised by the UK's Medicines and Healthcare products Regulatory Agency on 10 August 2026 for weight management and type 2 diabetes, making the UK the first country in Europe to approve the tablet [1]. The weight-management authorisation covers adults with a body mass index of 30 or above, and adults with a BMI between 27 and 30 who have at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity [1]. A second indication covers blood sugar control in type 2 diabetes that is not adequately controlled [1].
Even with that authorisation, the medicine is not currently available on the NHS, because NHS access requires a separate NICE evaluation [1]. Lilly began UK supply on 24 August through private prescription only, and the company has indicated private pricing of £100 to £120 per month [1].
Orforglipron is a small-molecule GLP-1 receptor agonist rather than a peptide [1]. Peptide drugs such as semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound, are broken down in the gut, which is why they are normally given by injection; a small molecule survives digestion intact [1]. The tablet is taken once daily at any time of day, with no food or water restrictions, and dosing begins at 0.8 mg and escalates through five further steps to 17.2 mg, with a minimum of one month spent at each level [1]. The most common side effects reported are nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain [1].
In the United States, the Food and Drug Administration approved orforglipron for obesity in April 2026, and Lilly submitted the medicine for type 2 diabetes in the US during the second quarter of 2026 [1].
Why it matters for patients
The NICE decision governs NHS access in the UK, not US availability. Orforglipron already has a US approval for obesity, and the UK appraisal does not change that [1]. What the open appraisal shows is that regulators and payers can reach different conclusions on the same product: a medicine can be authorised for sale and still not be covered by a national health system [1].
For people weighing an oral GLP-1 against an injected one, the formulation is the practical difference. Orforglipron is a once-daily tablet with no food or water timing requirements, while oral semaglutide requires a fasting window [1]. People in the UK who want the medicine now can only obtain it privately, at the pricing Lilly has indicated of £100 to £120 per month [1]. Whether US insurers will cover orforglipron, and on what terms, has not been reported here.
What happens next
The next dated marker is the expected publication date of 18 November 2026 listed on the appraisal [1]. NICE has not set a date for a second committee meeting, and it has not disclosed what additional information it asked Lilly to provide [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.